394 related articles for article (PubMed ID: 7514044)
41. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
[TBL] [Abstract][Full Text] [Related]
42. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
[TBL] [Abstract][Full Text] [Related]
43. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
44. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
45. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK
Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345
[TBL] [Abstract][Full Text] [Related]
46. [Tissue plasminogen activator, its inhibitor and other parameters of fibrinolysis in blood of patients operated for mild hypertrophy of the prostate].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F; Cwiklińska-Jurkowska M
Pol Tyg Lek; 1992 Dec 7-14; 47(49-50):1096-7. PubMed ID: 1284828
[TBL] [Abstract][Full Text] [Related]
47. Genetic markers of fibrinolytic responses of older persons to exercise training.
Kulaputana O; Ghiu I; Phares DA; Ferrell RE; Macko RF; Goldberg AP; Hagberg JM
Int J Sports Med; 2006 Aug; 27(8):617-22. PubMed ID: 16874588
[TBL] [Abstract][Full Text] [Related]
48. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
49. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
[TBL] [Abstract][Full Text] [Related]
50. [An analysis of DIC in patients with multiple organ failure--variations of the molecular makers and its clinical usefulness].
Gando S; Tedo I
Rinsho Ketsueki; 1990 Nov; 31(11):1774-9. PubMed ID: 2149574
[TBL] [Abstract][Full Text] [Related]
51. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.
Selgas R; Cuesta MV; Riñon C; Romero JR; de Alvaro F; Bajo MA; Sanchez-Sicilia L
Adv Perit Dial; 1992; 8():160-5. PubMed ID: 1361777
[TBL] [Abstract][Full Text] [Related]
52. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Kluft C; Jie AF; Rijken DC; Verheijen JH
Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
[TBL] [Abstract][Full Text] [Related]
53. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.
Chadarevian R; Bruckert E; Leenhardt L; Giral P; Ankri A; Turpin G
J Clin Endocrinol Metab; 2001 Feb; 86(2):732-7. PubMed ID: 11158038
[TBL] [Abstract][Full Text] [Related]
54. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease.
Oseroff A; Krishnamurti C; Hassett A; Tang D; Alving B
J Lab Clin Med; 1989 Jan; 113(1):88-93. PubMed ID: 2783330
[TBL] [Abstract][Full Text] [Related]
55. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man.
Landin K; Tengborn L; Chmielewska J; von Schenck H; Smith U
Thromb Haemost; 1991 Feb; 65(2):130-3. PubMed ID: 1905068
[TBL] [Abstract][Full Text] [Related]
56. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states.
Kruithof EK; Gudinchet A; Bachmann F
Thromb Haemost; 1988 Feb; 59(1):7-12. PubMed ID: 3129809
[TBL] [Abstract][Full Text] [Related]
57. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.
Jurado M; Páramo JA; Gutierrez-Pimentel M; Rocha E
Thromb Haemost; 1992 Nov; 68(5):516-20. PubMed ID: 1455397
[TBL] [Abstract][Full Text] [Related]
58. Peritoneal fluid and plasma fibrinolytic activity in women with pelvic inflammatory disease.
Dörr PJ; Brommer EJ; Dooijewaard G; Vemer HM
Thromb Haemost; 1992 Aug; 68(2):102-5. PubMed ID: 1412151
[TBL] [Abstract][Full Text] [Related]
59. [t-PA activity, antigen and PAI-1 antigen levels in blood obtained from the patients with cerebral infarction].
Yamada S; Yamada R; Ishii A; Ashikawa K; Nakamura M; Sasamata M; Watanabe S
Rinsho Byori; 1990 Jul; 38(7):819-24. PubMed ID: 2119465
[TBL] [Abstract][Full Text] [Related]
60. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels.
Juhan-Vague I; Alessi MC; Raccah D; Aillaud MF; Billerey M; Ansaldi J; Philip-Joet C; Vague P
Thromb Haemost; 1992 Jan; 67(1):76-82. PubMed ID: 1615488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
